[HTML][HTML] Increased peptide contacts govern high affinity binding of a modified TCR whilst maintaining a native pMHC docking mode

DK Cole, M Sami, DR Scott, PJ Rizkallah… - Frontiers in …, 2013 - frontiersin.org
DK Cole, M Sami, DR Scott, PJ Rizkallah, OY Borbulevych, PT Todorov, RK Moysey…
Frontiers in immunology, 2013frontiersin.org
Natural T cell receptors (TCRs) generally bind to their cognate pMHC molecules with weak
affinity and fast kinetics, limiting their use as therapeutic agents. Using phage display, we
have engineered a high affinity version of the A6 wild-type TCR (A6wt), specific for the
human leukocyte antigen (HLA-A∗ 0201) complexed with human T cell lymphotropic virus
type 111–19 peptide (A2-Tax). Mutations in just 4 residues in the CDR3β loop region of the
A6wt TCR were selected that improved binding to A2-Tax by nearly 1000-fold. Biophysical …
Natural T cell receptors (TCRs) generally bind to their cognate pMHC molecules with weak affinity and fast kinetics, limiting their use as therapeutic agents. Using phage display, we have engineered a high affinity version of the A6 wild-type TCR (A6wt), specific for the human leukocyte antigen (HLA-A0201) complexed with human T cell lymphotropic virus type 111–19 peptide (A2-Tax). Mutations in just 4 residues in the CDR3β loop region of the A6wt TCR were selected that improved binding to A2-Tax by nearly 1000-fold. Biophysical measurements of this mutant TCR (A6c134) demonstrated that the enhanced binding was derived through favorable enthalpy and a slower off-rate. The structure of the free A6c134 TCR and the A6c134/A2-Tax complex revealed a native binding mode, similar to the A6wt/A2-Tax complex. However, concordant with the more favorable binding enthalpy, the A6c134 TCR made increased contacts with the Tax peptide compared with the A6wt/A2-Tax complex, demonstrating a peptide-focused mechanism for the enhanced affinity that directly involved the mutated residues in the A6c134 TCR CDR3β loop. This peptide-focused enhanced TCR binding may represent an important approach for developing antigen specific high affinity TCR reagents for use in T cell based therapies.
Frontiers